Cited by 186Cancer-related Molecular PathwaysHeat shock proteins researchProtein Structure and Dynamics

The DOI matches its Crossref record; 103 of the 105 references it cites were found in a registry or an index.

Reactivation of mutant p53: molecular mechanisms and therapeutic potential

Selivanova, G, Wiman, K G·2007·Oncogene

Open this paper in CoChat — free account

Abstract

The p53 tumor suppressor gene is the most frequently mutated gene in cancer. Most p53 mutations are missense point mutations that cluster in the DNA-binding core domain. This results in distortion of core domain folding and disruption of DNA binding and transcriptional transactivation of p53 target genes. Structural studies have demonstrated that mutant p53 core domain unfolding is not irreversible. Mutant p53 is expressed at high levels in many tumors. Therefore, mutant p53 is a promising target for novel cancer therapy. Mutant p53 reactivation will restore p53-dependent apoptosis, resulting in efficient removal of tumor cells. A number of strategies for targeting mutant p53 have been designed, including peptides and small molecules that restore the active conformation and DNA binding to mutant p53 and induce p53-dependent suppression of tumor cell growth in vitro and in vivo. This opens possibilities for the clinical application of mutant p53 reactivation in the treatment of cancer.

Integrity signals

Registry

Crossref · 10.1038/sj.onc.1210295

Cites

103 of 103 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Live or let die: the cell's response to p53
Vousden, K. H., & Lü, X. (2002) · Nature reviews. Cancer · doi:10.1038/nrc864 · Cited by 3,231
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559 · cited 2×
“…more recent nuclear magnetic resonance (NMR) and X-ray studies on tumor-derived core domain mutants have revealed the structural impact of amino-acid residues that are most frequently mutated in human cancers (Cho et al., 1994; Wong et al., 1999; Joerger et al., 2004, 2005a, b; Ang et al., 2006).”
Background
The IARC TP53 database: new online mutation analysis and recommendations to users
Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P. (2002) · Human Mutation · doi:10.1002/humu.10081 · Cited by 1,248
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Self-citation
Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.
Gannon, J., Greaves, R. F., Iggo, R. D., & Lane, D. P. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08279.x · Cited by 970
The Rb/E2F pathway and cancer
Nevins, J. R. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.699 · Cited by 939
Pharmacological Rescue of Mutant p53 Conformation and Function
Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 802
Presence of a Potent Transcription Activating Sequence in the p53 Protein
Fields, S., & Jang, S. K. (1990) · Science · doi:10.1126/science.2144363 · Cited by 790
Differential induction of transcriptionally active p53 following UV or lonizing radiation: Defects in chromosome instability syndromes?
Lü, X. (1993) · Cell · doi:10.1016/0092-8674(93)90496-d · Cited by 773

Flagged first, then by citations

Show all 105 references

2 of the 105 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–185 of 185

Integrins and Mutant p53 on the Road to Metastasis
Selivanova, G., & Ivaska, J. (2009) · Cell · doi:10.1016/j.cell.2009.12.016 · Cited by 25
Self-citation
p53 as a therapeutic target
Staples, O. D., Steele, R. J., & Laı́n, S. (2008) · The Surgeon · doi:10.1016/s1479-666x(08)80034-0 · Cited by 24
PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells
Russo, D., Ottaggio, L., Penna, I., Foggetti, G., Fronza, G., Inga, A., & Menichini, P. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.10.031 · Cited by 23
RBBP6: a potential biomarker of apoptosis induction in human cervical cancer cell lines
Motadi, L. R., & Moela, P. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s100964 · Cited by 24
Styrylcoumarin 7-SC2 induces apoptosis in SW480 human colon adenocarcinoma cells and inhibits azoxymethane-induced aberrant crypt foci formation in BALB/c mice
Herrera-R, A., Naranjo, T. W., Celis, M. E. M., Moreno, G., Yepes, A. F., & Cardona‐Galeano, W. (2019) · Medicinal Chemistry Research · doi:10.1007/s00044-019-02487-2 · Cited by 22
Transition of amyloid/mutant p53 from tumor suppressor to an oncogene and therapeutic approaches to ameliorate metastasis and cancer stemness
Sengupta, S., Ghufran, S. M., Khan, A. A., Biswas, S., & Roychoudhury, S. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02831-4 · Cited by 20
Interaction between ZBP-89 and p53 mutants and its contribution to effects of HDACi on hepatocellular carcinoma
Zhang, C. Z. Y., Chen, G. G., Merchant, J. L., & Lai, P. B. S. (2012) · Cell Cycle · doi:10.4161/cc.11.2.18758 · Cited by 21
TP53 in Myelodysplastic Syndromes
Jiang, Y., Gao, S., Soubise, B., Douet‐Guilbert, N., Liu, Z., & Troadec, M. (2021) · Cancers · doi:10.3390/cancers13215392 · Cited by 22
Curcumin rescue p53Y220C in BxPC-3 pancreatic adenocarcinomas cell line: Evidence-based on computational, biophysical, and in vivo studies
Malhotra, L., Goyal, H., Jhuria, S., Dev, K., Kumar, S., Kumar, M., Kaur, P., & Ethayathulla, A. S. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129807 · Cited by 22
Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation
Ma, T., Yamada, S., Ichwan, S. J. A., Iseki, S., Ohtani, K., Otsu, M., & Ikeda, M. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.11.161 · Cited by 19
Synthesis and Chemopreventive Potential of 5-FU/Genistein Hybrids on Colorectal Cancer Cells
Moreno, G., Castrillón-L, W., Herrera‐Ramírez, A., Yepes, A. F., Quintero‐Saumeth, J., & Cardona‐Galeano, W. (2022) · Pharmaceuticals · doi:10.3390/ph15101299 · Cited by 19
Decoding the functional impact of the cancer genome through protein–protein interactions
Fu, H., Mo, X., & Ivanov, A. A. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-024-00784-6 · Cited by 22
The 19q13 KRAB Zinc-finger protein ZFP82 suppresses the growth and invasion of esophageal carcinoma cells through inhibiting NF-κB transcription and inducing apoptosis
Ye, L., Xiang, T., Yu, F., Zhang, D., Li, L., Zhang, C., He, X., Xiang, Q., Tao, Q., & Ren, G. (2018) · Epigenomics · doi:10.2217/epi-2018-0092 · Cited by 19
Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib
Wang, X., SONG, H., Yu, Q., Liu, Q., Wang, L., Liu, Z., & Yu, Z. (2014) · Oncology Reports · doi:10.3892/or.2014.3665 · Cited by 17
Anti-cancer Potential of Captopril and Botulinum Toxin Type-A and Associated p53 Gene Apototic Stimulating Activity.
Shebl, R. I. (2019) · PubMed Central · doi:10.22037/ijpr.2019.1100800 · Cited by 17
Dodonaea viscosa Jacq. induces cytotoxicity, antiproliferative activity, and cell death in colorectal cancer cells via regulation of caspase 3 and p53
Herrera-Calderón, O., Herrera‐Ramírez, A., Cardona‐Galeano, W., Melgar-Merino, E. J., Chávez, H., Pari-Olarte, J. B., Loyola-Gonzales, E., Kong-Chirinos, J. F., Almeida-Galindo, J. S., Peña-Rojas, G., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1197569 · Cited by 16
Gentian violet induces wtp53 transactivation in cancer cells
Garufi, A., D’Orazi, V., Arbiser, J. L., & D’Orazi, G. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2304 · Cited by 15
Function and regulation of F‑box/WD repeat‑containing protein 7 (Review)
Zhang, Z., Hu, Q., Xu, W., Liu, W., Liu, M., Sun, Q., Zeng, Y., Fan, G., Qin, Y., Xu, X., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11728 · Cited by 14
Viability and cell cycle studies of metastatic triple negative breast cancer cells using low voltage electrical pulses and herbal curcumin
Mittal, L., Raman, V., Camarillo, I. G., Garner, A. L., & Sundararajan, R. (2018) · Biomedical Physics & Engineering Express · doi:10.1088/2057-1976/aaf2c3 · Cited by 14
p53-targeted cancer pharmacotherapy: move towards small molecule compounds
Kim, S.-H., & Dass, C. R. (2011) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2010.01248.x · Cited by 14
Dual Modulators of p53 and Cyclin D in ER Alpha Signaling by Albumin Nanovectors Bearing Zinc Chaperones for ER-positive Breast Cancer Therapy
Sundar, P. S., Naresh, P., Justin, A., Wadhwani, A., Mohankumar, S. K., & Selvaraj, J. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520999201124212347 · Cited by 13
Nutri-PEITC Jelly Significantly Improves Progression-Free Survival and Quality of Life in Patients with Advanced Oral and Oropharyngeal Cancer: A Blinded Randomized Placebo-Controlled Trial
Lam‐ubol, A., Sukhaboon, J., Rasio, W., Tupwongse, P., Tangshevinsirikul, T., & Trachootham, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097824 · Cited by 13
Polypharmacology of small molecules targeting the ubiquitin-proteasome and ubiquitin-like systems
Amelio, I., Landré, V., Knight, R. A., Lisitsa, A., Melino, G., & Antonov, A. V. (2015) · Oncotarget · doi:10.18632/oncotarget.3917 · Cited by 13
Proapoptotic Effect and Molecular Docking Analysis of Curcumin–Resveratrol Hybrids in Colorectal Cancer Chemoprevention
Moreno, G., Herrera-R, A., Yepes, A. F., Naranjo, T. W., & Cardona‐Galeano, W. (2022) · Molecules · doi:10.3390/molecules27113486 · Cited by 13
CircXPO1 Promotes Glioblastoma Malignancy by Sponging miR-7-5p
Wang, X., Wang, J., An, Z., Yang, A., Qiu, M. S., & Tan, Z. (2023) · Cells · doi:10.3390/cells12060831 · Cited by 12
An Amphiphilic Peptide Induces Apoptosis Through the miR29b-p53 Pathway in Cancer Cells
Kim, S., Lee, J., Kang, I., Hyun, S., Yu, J., & Shin, C. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.45 · Cited by 12
Homeobox protein VentX induces p53-independent apoptosis in cancer cells
Gao, H., Wu, B., Le, Y., & Zhu, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.9238 · Cited by 12
α-Mangostin induces G1 cell cycle arrest in HCT116 cells through p38MAPK-p16INK4a pathway
Korm, S., Jeong, H., Kwon, O., Park, J., Cho, H., Kim, Y., Chin, Y., & Cha, H. (2015) · RSC Advances · doi:10.1039/c5ra00780a · Cited by 12
TP53 transcription factor for the NEDD9/HEF1/Cas-L gene: potential targets in Non-Small Cell Lung Cancer treatment
Rousseau, B., Jacquot, C., PALABE, J. L., Malleter, M., Tomasoni, C., Boutard, T., Sakanyan, V. A., & Roussakis, C. (2015) · Scientific Reports · doi:10.1038/srep10356 · Cited by 11
In-vitro Chemopreventive Potential of a Chromone from Bomarea setacea (ALSTROEMERIACEAE) against Colorectal Cancer.
Herrera-R, A., Moreno, G., Marín, P. A., Vásquez, I., Naranjo, E., Álzate, F., & Cardona‐Galeano, W. (2021) · Europe PMC (PubMed Central) · doi:10.22037/ijpr.2020.113745.14466 · Cited by 11
Susceptibility for NSAIDs-Induced Apoptosis Correlates to p53 Gene Status in Gastric Cancer Cells
Zhang, Y., Dai, Q., Wu, S., Zhu, H.-Y., Shen, G.-F., Li, E.-L., & Xiao, S. (2008) · Cancer Investigation · doi:10.1080/07357900801944872 · Cited by 11
RETRACTED: Reactivation of p53 in cells expressing hepatitis B virus X‐protein involves p53 phosphorylation and a reduction of Hdm2
Wang, J.-H., Yun, C., Kim, S., Chae, S., Lee, Y. I., Kim, W., Lee, J., Kim, W., & Cho, H. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00754.x · Cited by 11
Retracted
PRIMA-1 induces caspase-mediated apoptosis in acute promyelocytic leukemia NB4 cells by inhibition of nuclear factor-κB and downregulation of Bcl-2, XIAP, and c-Myc
Farhadi, E., Safa, M., Sharifi, A. M., & Bashash, D. (2016) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000426 · Cited by 11
Virtual screening using covalent docking to find activators for G245S mutant p53
Omar, S. I., Lepre, M. G., Morbiducci, U., Deriu, M. A., & Tuszyński, J. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200769 · Cited by 10
Synergistic and additive effect of retinoic acid in circumventing resistance to p53 restoration
Larsson, C. A., Moyer, S. M., Liu, B., Michel, K. A., Pant, V., Yang, P., Wong, J., El‐Naggar, A. K., Krahe, R., & Lozano, G. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1719001115 · Cited by 10
Disease-modifying therapy for proteinopathies: Can the exception become the rule?
Bitan, G. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.07.010 · Cited by 10
The Interaction of Metal Compounds with Protein Targets: New Tools in Medicinal Chemistry and Chemical Biology
Miller, J. J., Gomes, L. M., Storr, T., & Casini, A. (2017) · Wiley eBooks · doi:10.1002/9781119951438.eibc2499 · Cited by 10
Progress in triple negative breast carcinoma pathophysiology: Potential therapeutic targets
Yu, K., Rohr, J. M., Liu, Y., Li, M., Xu, J., Wang, K., Chai, J., Zhao, D., Liu, Y., Ma, J., et al. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.152874 · Cited by 9
Using high-throughput sequencing transcriptome data for INDEL detection: challenges for cancer drug discovery
Wajnberg, G., & Passetti, F. (2016) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1143813 · Cited by 9
Prima-1 and APR-246 in Cancer Therapy
Zatloukalová, P., Galoczová, M., & Vojtěšek, B. (2018) · Klinicka onkologie · doi:10.14735/amko20182s71 · Cited by 11
PRIMA-1MET induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 protein
Stuber, G., Flaberg, E., Petrányi, G., Ötvös, R. H.-G., Rökaeus, N., Kashuba, E., Wiman, K. G., Klein, G., & Székely, L. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-23 · Cited by 8
Self-citation
Lipopeptides in promoting signals at surface/interface of micelles: Their roles in repairing cellular and nuclear damages
Saâdi, S., Saari, N., Ghazali, H. M., Mohammed, A. S., Hamid, A. A., Nacer, N. E., & Anwar, F. (2021) · Food Bioscience · doi:10.1016/j.fbio.2021.101522 · Cited by 7
Suppression of gain-of-function mutant p53 with metabolic inhibitors reduces tumor growthin vivo
Jung, C. L., Mun, H., Jo, S., Oh, J., Lee, C., Choi, E., Jang, S. J., & Suh, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.12758 · Cited by 7
Role of senescent tumor cells in building a cytokine shield in the tumor microenvironment: mathematical modeling
Kim, Y., Lee, J.-H., Lee, C., & Lawler, S. E. (2022) · Journal of Mathematical Biology · doi:10.1007/s00285-022-01850-z · Cited by 7
Negative Regulation-Resistant p53 Variant Enhances Oncolytic Adenoviral Gene Therapy
Koo, T., Choi, I., Kim, M., Lee, J., Oh, E., Kim, J., & Yun, C. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.114 · Cited by 6
Evidence for a non-stochastic two-field hypothesis for persistent skin cancer risk
Konger, R. L., Ren, L., Sahu, R. P., Derr-Yellin, E. C., & Kim, Y. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-75864-2 · Cited by 6
Methylation‑regulated ZNF545 inhibits growth of the p53‑mutant KYSE150 cell line by inducing p21 and Bax
Yu, F., Wang, Y., Fu, S., Liu, D., & Lin, S. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7737 · Cited by 6
Pharmacoepigenetic aspects of gene polymorphism on drug therapies: effects of DNA methylation on drug response
Gomez, A. V., & Ingelman‐Sundberg, M. (2008) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2.1.55 · Cited by 5
POTENTIAL COUMARIN THIOSEMICARBAZONE HYBRIDS AS BRCA-1 MIMETICS FOR ER POSITIVE BREAST CANCER THERAPY: AN IN-SILICO APPROACH
Selvaraj, J. (2021) · Journal of medical pharmaceutical and allied sciences · doi:10.22270/jmpas.v10i4.1383 · Cited by 5
Recent advances in mutant p53 and novel personalized strategies for cancer therapy
Lu, S.-Q., Jia, S., & Luo, Y. (2011) · Hereditas (Beijing) · doi:10.3724/sp.j.1005.2011.00539 · Cited by 5
Structural and functional characterisation of HepTH1-5 peptide as a potential hepcidin replacement
Azemin, W.-A., Alias, N., Ali, A. M., & Shamsir, M. S. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.2011415 · Cited by 5
When mutant p53 plays hide and seek: a new challenge for diagnosis and therapy?
Soussi, T., & Hjortsberg, L. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.11.002 · Cited by 5
Therapeutic potential of antisense oligodeoxynucleotides in downregulating p53 oncogenic mutations in cancers
Xie, Z., Chng, W. J., Tay, K.-G., Liu, S. C., Zhou, J., & Chen, C.-S. (2010) · Biotechnology Letters · doi:10.1007/s10529-010-0423-5 · Cited by 4
Unlocking the Gateway: The Spatio-Temporal Dynamics of the p53 Family Driven by the Nuclear Pores and Its Implication for the Therapeutic Approach in Cancer
Ikliptikawati, D. K., Makiyama, K., Hazawa, M., & Wong, R. W.-C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137465 · Cited by 3
Recombinant GnRH-p53 protein sensitizes breast cancer cells to 5-fluorouracil-induced apoptosis in vitro and in vivo
Lu, Y. W., Zhang, Z., Yan, Z., Chen, L., Deng, W., Lotze, M. T., Wang, Z., Lin, X., & Li, L. (2013) · APOPTOSIS · doi:10.1007/s10495-013-0863-1 · Cited by 3
Zinc and Zinc-Dependent Proteins in Cancer and Chemotherapeutics
Guynn, J. M., & Chan, E. (2017) · Molecular and integrative toxicology · doi:10.1007/978-3-319-55448-8_4 · Cited by 4
High p53 Protein Level Is a Negative Prognostic Marker for Pancreatic Adenocarcinoma
Klein, S. M., Bożko, M., Toennießen, A., Rangno, D., & Bozko, P. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212307 · Cited by 2
Dicentrine and its N-oxide derivatives induces apoptotic and necrotic cell death in prostate cancer cell lines
Machado, R. S., Tristão, D. C., Araújo, N. M., Seif, E. J. M., da Cruz, K. A. S., Morale, M. G., Rubio, I. G. S., Lago, J. H. G., & Tamura, R. E. (2025) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2025.100257 · Cited by 2
Current Concepts and New Insights from Mouse Models of Mammary Tumors on Epithelial Mesenchymal Transition and its Synergy with Mutant p53
Piersigilli, A., Borowsky, A., Chen, Q., Hubbard, N. E., & Cardiff, R. D. (2015) · Journal of Analytical Oncology · doi:10.6000/1927-7229.2015.04.04.8 · Cited by 2
P53: Its Role in Carcinogenesis And Also A Novel Target for Anti-Cancer Therapy
Agrawal, S. N. (2016) · IOSR Journal of Dental and Medical Sciences · doi:10.9790/0853-1509072834 · Cited by 2
P53, ROS: Redox Regulation Signaling, Metabolic Reprogramming, and Autophagy in Cancer
Bansal, M. P. (2023) · Springer eBooks · doi:10.1007/978-981-99-7342-2_7 · Cited by 2
Role of p53 in Human Cancers
Coşkun, K. A., Tutar, M., Al, M., Yurttaş, A. G., Abay, E. C., Yurekli, N., Yeman-Kıyak, B., Çifci, K. U., & Tutar, Y. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.101961 · Cited by 2
Salivary gland cancer in Finland: Incidence, histological distribution, outcome and prognostic factors
Luukkaa, H. (2010) · UTUPub (University of Turku) · Cited by 2
MicroRNA-29a plays a prominent role in PRIMA-1Met-induced apoptosis in ovarian cancer cells
İmir, N. (2020) · Archives of Biological Sciences · doi:10.2298/abs191128011i · Cited by 1
Senescence and the Microenvironment
Rai, M. K., Yadav, P., Katailiha, A. S., Singh, A. K., & Yadav, S. K. (2025) · Springer eBooks · doi:10.1007/978-981-96-1041-9_3 · Cited by 1
Senescence, Apoptosis, and Cancer
Dimri, M., & Dimri, G. P. (2016) · Springer eBooks · doi:10.1007/978-1-59745-458-2_10 · Cited by 1
GingerenoneA overcomes dexamethasone resistance by activating apoptosis and inhibiting cell proliferation in pediatric T‐ALL cells
Katebi, M., Rahgozar, S., Kazemi, F., Rahmani, S., & Dorcheh, S. N. (2023) · Cancer Science · doi:10.1111/cas.15936 · Cited by 1
Energy Generating Pathways and the Tumor Suppressor p53
Corcoran, C. A., Huang, Y. K., & Sheikh, M. S. (2008) · Springer eBooks · doi:10.1007/978-0-387-84835-8_8 · Cited by 1
Apoptose-Mechanismen in der Onkogenese von Hauttumoren
Leverkus, M. (2008) · Aktuelle Dermatologie · doi:10.1055/s-2008-1077553 · Cited by 1
Selective targeting of p53 gain-of-function mutants in cancer
Padmanabhan, A. (2018) · Oncoscience · doi:10.18632/oncoscience.408 · Cited by 1
Regulation of the p53 Tumor‐Suppressor Protein by Ubiquitin and Ubiquitin‐Like Molecules
Xirodimas, D. P. (2007) · Wiley eBooks · doi:10.1002/9783527619320.ch2c
Mechanistic studies of APR-246 in leukemia
Ali, D. (2013) · Figshare
PHARMACOLOGICAL TARGETING OF P53 PATHWAY ALTERATIONS IN TUMORS
Zhao, Y. (2010) · Figshare
Induction of apoptosis promoted by Bang52; a small molecule that downregulates Bcl-xL
Rossi, M., Bang, J.-K., Mazur, S. J., Iera, J. A., Phillips, D. C., Zambetti, G. P., & Appella, D. H. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.067
Testicular cancer – response adapted treatment, prognostic markers and survivorship issues
Olofsson, S.-E. (2015) · Lund University Publications (Lund University)
Selective Inhibition of p53 Dominant Negative Mutation by shRNA Resulting in Partial Restoration of p53 Activity
Chen, E. I.-T., Wu, J., Su, W.-H., Wang, T., & Au, L. (2009) · doi:10.6136/jms.2009.29(4).179
Molecular mechanism of BMP4/Xom signal transduction
Gao, H. (2008) · doi:10.17760/d10017082
CARACTERIZACIÓN DEL EFECTO ANTICANCEROSO E IDENTIFICACIÓN DE DIANAS MOLECULARES DE PRINCIPIOS ACTIVOS PROCEDENTES DE Serratia marcescens
de Medicina, F. (2007)
Biomolecular hydration in protein-protein interaction, protein stability and aggregation and lead optimization : computational studies
Pradhan, M. R. (2017) · doi:10.32657/10356/69994
An investigation of mutant p53 function.
Noll, J. E. (2011) · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
OVER KANSERİ HÜCRELERİNDE PRİMA-1 Met TEDAVİSİNE YANIT OLARAK DEĞİŞEN miRNA EKSPRESYON ANALİZİ
İmir, N., Aydemir, E. A., & Şimşek, E. (2020) · Sağlık Bilimleri Dergisi · doi:10.34108/eujhs.543409
Regulation of the p53 Tumor‐Suppressor Protein by Ubiquitin and Ubiquitin‐Like Molecules
Xirodimas, D. P. (2007) · Wiley eBooks · doi:10.1002/9783527620234.ch2
Data from Peptide Aptamers Targeting Mutant p53 Induce Apoptosis in Tumor Cells
Guida, E., Bisso, A., Fenollar‐Ferrer, C., Napoli, M., Anselmi, C., Girardini, J. E., Carloni, P., & Sal, G. D. (2023) · doi:10.1158/0008-5472.c.6496331.v1
Functional restoration of conformational (R175H) and contact (R273H) mutant p53 by Bacillus-derived Hydroxymycotrienin A in non-small cell lung cancer: a computational approach
Rufus, A. C., Sidharth Kumar, N., Ramasamy, M., & Elangovan, E. (2026) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2026.1875897
BindingDB Entry 50021131: An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53.
BindingDB (2025) · UC San Diego · doi:10.7270/q2571hks

Authors: Selivanova, G., & Wiman, K. G.
Affiliations: Karolinska Institutet (SE)
Corresponding author: Wiman, K G
ORCID: Selivanova, G
Wiman, K G
Venue: Oncogene
Publisher: Springer Science and Business Media LLC
Published: 2007-04-02
Volume: 26
Issue: 15
Pages: 2243-2254
ISSN: 0950-9232 (ISSN-L)
1476-5594
DOI: 10.1038/sj.onc.1210295
OpenAlex: W2025977492
Cited by: 186
References: 105
Citations by year: 2026: 1 · 2025: 4 · 2024: 3 · 2023: 7 · 2022: 6 · 2021: 9 · 2020: 8 · 2019: 6 · 2018: 9 · 2017: 7 · 2016: 16 · 2015: 11 · 2014: 9 · 2013: 11 · 2012: 7
FWCI: 1.98
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Oncogene (publishedVersion)
PubMed (publishedVersion)
Funders: Cancerfonden
Karolinska Institutet
Cancerföreningen i Stockholm
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
Keywords: mutant p53, p53 reactivation, p53 tumor suppressor, missense mutations, protein unfolding, p53-dependent apoptosis, transcriptional activation, cancer therapy
MeSH terms: Humans, Mutation, Neoplasms, Protein Conformation, Tumor Suppressor Protein p53

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Reactivation of mutant p53: molecular mechanisms and therapeutic potential

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks